Clinical Specificity of RBC Alloantibodies Studied in Pregnant Women
By LabMedica International staff writers Posted on 05 Sep 2019 |
Image: The Ortho ProVue automated blood bank analyzer (Photo courtesy of Ortho Clinical Diagnostics).
Maternal red cell immunoglobulin G (IgG) antibodies can cross the placenta and cause hemolysis of fetal red cells in case of antigenic differences between maternal and fetal red blood cells (RBCs), leading to hemolytic disease of the fetus and newborn (HDFN).
Although the incidence of anti-D associated HDFN has drastically reduced with Rh immune globulin prophylaxis, HDFN due to other maternal red cell alloantibodies still remains a concern. Prevalence and specificities of clinically significant red cell alloantibodies in pregnant females have rarely been reported in the USA.
Medical Laboratory Scientists at the Beaumont Hospital (Royal Oak, MI, USA) conducted a retrospective chart review to determine the prevalence and specificity of clinically significant red cell alloantibodies in pregnant females who delivered at the hospital between May 1, 2017, and December 31, 2017. A total of 4,545 pregnant females with a valid ABO/RhD type and valid red cell antibody screen were included. ABO/RhD typing and antibody screening were performed using the gel card methodology with automated blood bank analyzers Ortho ProVue, whereas the specificity of antibodies was identified with indirect antiglobulin testing using the manual gel card methodology.
The team reported that out of the 4,545 females, 440 had a positive red cell antibody screen. Of these 440 females, 34 had clinically significant alloantibodies, giving an overall prevalence of 0.74%. Anti-E was the most frequently identified significant alloantibody followed by anti-K. The most prevalent significant alloantibodies in RhD positive and RhD negative females were anti-E and anti-K, respectively. Significant association was found between RhD type and the presence of clinically significant alloantibodies amongst females with a positive antibody screen. Out of 34 females with clinically significant red cell alloantibodies, six (17.6%) females had more than one clinically significant alloantibody; all of them being multigravida, indicating a higher risk of multiple red cell alloimmunization with subsequent pregnancies.
The authors concluded that anti-E and anti-K were the two most frequently identified clinically significant red cell alloantibodies in their study population. The findings of the study aim to re-emphasize the importance of screening and detection of red cell alloantibodies early in pregnancy to help identify and appropriately manage high-risk pregnancies, in addition to increasing the understanding amongst pregnant females about these antibodies and the associated risk of HDFN. The study was published on August 13, 2019, in the Journal of Blood Medicine.
Related Links:
Beaumont Hospital
Although the incidence of anti-D associated HDFN has drastically reduced with Rh immune globulin prophylaxis, HDFN due to other maternal red cell alloantibodies still remains a concern. Prevalence and specificities of clinically significant red cell alloantibodies in pregnant females have rarely been reported in the USA.
Medical Laboratory Scientists at the Beaumont Hospital (Royal Oak, MI, USA) conducted a retrospective chart review to determine the prevalence and specificity of clinically significant red cell alloantibodies in pregnant females who delivered at the hospital between May 1, 2017, and December 31, 2017. A total of 4,545 pregnant females with a valid ABO/RhD type and valid red cell antibody screen were included. ABO/RhD typing and antibody screening were performed using the gel card methodology with automated blood bank analyzers Ortho ProVue, whereas the specificity of antibodies was identified with indirect antiglobulin testing using the manual gel card methodology.
The team reported that out of the 4,545 females, 440 had a positive red cell antibody screen. Of these 440 females, 34 had clinically significant alloantibodies, giving an overall prevalence of 0.74%. Anti-E was the most frequently identified significant alloantibody followed by anti-K. The most prevalent significant alloantibodies in RhD positive and RhD negative females were anti-E and anti-K, respectively. Significant association was found between RhD type and the presence of clinically significant alloantibodies amongst females with a positive antibody screen. Out of 34 females with clinically significant red cell alloantibodies, six (17.6%) females had more than one clinically significant alloantibody; all of them being multigravida, indicating a higher risk of multiple red cell alloimmunization with subsequent pregnancies.
The authors concluded that anti-E and anti-K were the two most frequently identified clinically significant red cell alloantibodies in their study population. The findings of the study aim to re-emphasize the importance of screening and detection of red cell alloantibodies early in pregnancy to help identify and appropriately manage high-risk pregnancies, in addition to increasing the understanding amongst pregnant females about these antibodies and the associated risk of HDFN. The study was published on August 13, 2019, in the Journal of Blood Medicine.
Related Links:
Beaumont Hospital
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data